Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
HL
Hodgkin lymphoma
PET adapted
chemotherapy
radiotherapy
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
25
08
2021
received:
07
05
2021
accepted:
26
08
2021
pubmed:
11
9
2021
medline:
18
3
2022
entrez:
10
9
2021
Statut:
ppublish
Résumé
The management of Hodgkin lymphoma (HL) has undergone significant changes in recent years. Due to the predilection of HL to affect younger patients, balancing cure and treatment-related morbidity is a constant source of concern for physicians and patients alike. Positron emission tomography adapted therapy has been developed for both early and advanced stage HL to try and improve the outcome of treatment, while minimising toxicities. The aim of this review is to digest the plethora of studies recently conducted and provide some clear, evidence-based practice statements to simplify the management of HL.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2119-2128Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Steven Swerdlow EC, Harris N, Jaffe E. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2017.
Australian Institute of Health and Welfare Statistics (AIHW). Statistics ICD-10 C81 report. Canberra: AIHW; 2019.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059-68.
Eghbali H, Raemaekers J, Carde P, EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol Suppl 2005; 66: 135-40.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-14.
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol 2019; 37: 2835-45.
Andre MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2017; 35: 1786-94.
Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 2015; 372: 1598-607.
Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med 2016; 374: 2419-29.
Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012; 366: 399-408.
Campbell BA, Voss N, Pickles T, Morris J, Gascoyne RD, Savage KJ et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol 2008; 26: 5170-4.
Wirth A, Mikhaeel NG, Aleman BMP, Pinnix CC, Constine LS, Ricardi U et al. Involved site radiation therapy in adult lymphomas: an overview of International Lymphoma Radiation Oncology Group guidelines. Int J Radiat Oncol Biol Phys 2020; 107: 909-33.
Evens AM, Cilley J, Ortiz T, Gounder M, Hou N, Rademaker A et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007; 137: 545-52.
Wongso D, Fuchs M, Plutschow A, Klimm B, Sasse S, Hertenstein B et al. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin Study Group. J Clin Oncol 2013; 31: 2819-24.
NSW Government. Cancer Treatments Online. Available from URL: https://www.eviq.org.au
Klimm B, Goergen H, Fuchs M, von Tresckow B, Boll B, Meissner J et al. Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann Oncol 2013; 24: 3070-6.
Herbst C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 2010; 95: 494-500.
Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 1916-27.
Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-52.
von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012; 30: 907-13.
Gillessen S, Plutschow A, Fuchs M, Markova J, Greil R, Topp M et al. Dose-Intensification of Early Unfavorable Hodgkin Lymphoma: Long Term Follow Up of the German Hodgkin Study Group (GHSG) HD 14 Trial. Orlando, FL: American Society of Hematology; 2019.
Borchmann P, Plutschow A, Kobe C, Greil R, Meissner J, Topp MS et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22: 223-34.
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.
Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2017;CD007941.
Trotman J, Fosså A, Federico M, Stevens L, Kirkwood A, Clifton-Hadley L et al. Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: longer follow up confirms efficacy of de-escalation after a negative interim PET scan (CRUK/07/033). Hematol Oncol 2017; 35: 65-7.
Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-52.
Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M et al. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 2014; 165: 112-6.
Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2018; 390: 2790-802.
Kreissl S, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D et al., eds. PET Guided Treatment in Patients with Advanced Stage Hodgkin Lymphoma: Follow Up Analysis of PET-2 Negative Patients in the HD18 Trial by the German Hodgkin Study Group. European Haematology Association; 2020.
Borchmann P. HD 21 for Advanced Stages - Treatment Optimization Trial in the First-Line Treatment of Advanced Stage Hodkin Lymphoma: Comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD. 2017, Version 5.0.
Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2019; 20: 202-15.
Connors JM, Radford JA. Brentuximab vedotin for stage III or IV Hodgkin's lymphoma. N Engl J Med 2018; 378: 1560-1.
Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E et al. Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: three-year update of the ECHELON-1 study. J Clin Oncol 2019; 37: 7532.
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791-9.
Gallamini A, Rossi A, Patti C, Picardi M, Romano A, Cantonetti M et al. Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL/FIL HD0607 trial. J Clin Oncol 2020; 38: 3905-13.
Boll B, Gorgen H. The treatment of older Hodgkin lymphoma patients. Br J Haematol 2019; 184: 82-92.
Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 2012; 119: 692-5.
Boll B, Gorgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 2013; 31: 1522-9.
Boll B, Goergen H, Behringer K, Brockelmann PJ, Hitz F, Kerkhoff A et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127: 2189-92.
Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2015; 385: 1418-27.
Boll B, Bredenfeld H, Gorgen H, Halbsguth T, Eich HT, Soekler M et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 2011; 118: 6292-8.
Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma 2007; 48: 570-6.
Favier O, Heutte N, Stamatoullas-Bastard A, Carde P, Van't Veer MB, Aleman BM et al. Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer 2009; 115: 1680-91.
Patel CG, Michaelson E, Chen YH, Silver B, Marcus KJ, Stevenson MA et al. Reduced mortality risk in the recent era in early-stage Hodgkin lymphoma patients treated with radiation therapy with or without chemotherapy. Int J Radiat Oncol Biol Phys 2018; 100: 498-506.
Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431-9.
Bhatti P, Veiga LH, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 2010; 174: 741-52.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma (Version 4.2021). NCCN; 2021 [updated 2021 Apr 20; cited 2021 19 Jul]. Available from URL: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf
Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med 2015; 373: 2499-511.
van Leeuwen FE, Ng AK. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program 2016; 2016: 323-30.
Schonfeld SJ, Gilbert ES, Dores GM, Lynch CF, Hodgson DC, Hall P et al. Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. J Natl Cancer Inst 2006; 98: 215-8.
Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. J Clin Oncol 2012; 30: 2745-52.
Krul IM, Opstal-van Winden AWJ, Aleman BMP, Janus CPM, van Eggermond AM, De Bruin ML et al. Breast cancer risk after radiation therapy for Hodgkin lymphoma: influence of gonadal hormone exposure. Int J Radiat Oncol Biol Phys 2017; 99: 843-53.
Ng AK. Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects. Blood 2014; 124: 3373-9.
Inskip PD, Sigurdson AJ, Veiga L, Bhatti P, Ronckers C, Rajaraman P et al. Radiation-related new primary solid cancers in the childhood cancer survivor study: comparative radiation dose response and modification of treatment effects. Int J Radiat Oncol Biol Phys 2016; 94: 800-7.
De Bruin ML, Sparidans J, van't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009; 27: 4239-46.
Holmqvist AS, Chen Y, Berano Teh J, Sun C, Birch JM, van den Bos C et al. Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-identification of high-risk populations to guide surveillance: a report from the Late Effects Study Group. Cancer 2019; 125: 1373-83.
Kumar V, Garg M, Chandra AB, Mayorga VS, Ahmed S, Ailawadhi S. Trends in the risks of secondary cancers in patients with Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2018; 18: 576-89.e1.
Conway JL, Connors JM, Tyldesley S, Savage KJ, Campbell BA, Zheng YY et al. Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2017; 97: 35-41.
Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2014; 123: 1658-64.
Bhatt VR, Giri S, Verma V, Dahal S, Shah BK, Pathak R et al. Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma. Future Oncol 2016; 12: 1565-75.
Chowdhry AK, Fung C, Chowdhry VK, Bergsma D, Dhakal S, Constine LS et al. A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma. Leuk Lymphoma 2018; 59: 1180-7.
Wattson DA, Hunink MG, DiPiro PJ, Das P, Hodgson DC, Mauch PM et al. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis. Int J Radiat Oncol Biol Phys 2014; 90: 344-53.
Stone CR, Mickle AT, Boyne DJ, Mohamed A, Rabi DM, Brenner DR et al. Treatment for lymphoma and late cardiovascular disease risk: a systematic review and meta-analysis. Health Sci Rep 2019; 2: e135.
Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 2768-801.
Jona A, Miltenyi Z, Ujj Z, Garai I, Szilasi M, Illes A. Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity. Expert Opin Drug Saf 2014; 13: 1291-7.
Inskip PD, Veiga LHS, Brenner AV, Sigurdson AJ, Ostroumova E, Chow EJ et al. Hypothyroidism after radiation therapy for childhood cancer: a report from the childhood cancer survivor study. Radiat Res 2018; 190: 117-32.
Inskip PD, Veiga LHS, Brenner AV, Sigurdson AJ, Ostroumova E, Chow EJ et al. Hyperthyroidism after radiation therapy for childhood cancer: a report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys 2019; 104: 415-24.
Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013; 31: 231-9.
Mulder RL, Hudson MM, Bhatia S, Landier W, Levitt G, Constine LS et al. Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer from the International Guideline Harmonization Group. J Clin Oncol 2020; 38: 4194-207.
International Guideline Harmonization Group (IGHG) for Late Effects of Childhood Cancer. IGHG; 2019. Available from URL: http://www.ighg.org/
Children's Oncology Group. Long-Term Follow-up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers Version 5.0. Children's Oncology Group; 2018 [updated 2018 Oct; cited 2019 Dec 29]. Available from URL: http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf
Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015; 16: e123-36.